PEPG - Pepgen Inc
NYSE * Health Care * Biotechnology
$1.70
+$0.03 (+1.80%)
About Pepgen Inc
PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company engages in the development of PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and FREEDOM2-DM1, which is in Phase 2 for the treatment of myotonic dystrophy type 1. It is also involved in FREEDOM-OLE, an open label expansion study. The company was founded in 2018 and is based in Boston, Massachusetts.
PEPG Key Statistics
Market Cap
$117.50M
P/B Ratio
0.79
EPS
$-2.12
Employees
56
How PEPG Compares to Peers
P/E Rank
N/A
of 5
Margin Rank
N/A
of 5
Growth Rank
N/A
of 5
Size Rank
#6
of 6
Pepgen Inc Company Information
- Headquarters
- Massachusetts; U.S.A
- Website
- www.pepgen.com
- Sector
- Health Care
- Industry
- Biotechnology